Danish biotech company Novozymes started its days in 1925 as a producer of insulin. Today its core business is industrial enzymes, microorganisms, and biopharmaceutical ingredients. Constantly breaking new ground and expanding rapidly, the industry leader also explores new business opportunities in technologies such as fermentation and the production of proteins. In 2007, Novozymes acquired Canadian company Philom Bios, and in 2010 it closed a deal to buy the Brazilian agriculture company Turfal. Another deal was struck in 2011, which saw Novozyme acquire EMD/Merck Crop Bioscience. The company’s regional offices are located in Brazil, China, Europe, India and North America.